Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine
Simply fill out the form below to receive reminders by e-mail. GARDASIL® is given as 3 injections (shots) over 6 months (first dose, 2 months, 6 months). Making sure you get all 3 doses will allow you to get the full benefits.
Your e-mail address will only be used to provide reminders and will not be retained following this use.
Personal Information about you will be accessible to Merck, including its Affiliates, and to individuals and organizations that use Personal Information solely for and at the direction of Merck. Uses and disclosures of Personal Information by external individuals and organizations acting on the behalf of Merck are governed by contracts that require Personal Information to be protected appropriately. Personal Information about you will only be used by Merck and individuals and organizations working on its behalf and disclosed by Merck to individuals and organizations working on its behalf, in a manner consistent with this Policy, other applicable privacy notices, and as explicitly permitted or required by applicable laws, rules and regulations. Furthermore, use of Personal Information is limited to those employees of Merck and its Agents who have an identified “need-to-know”. For more information about how Merck protects personal information about you, please read Merck's
To retrieve this information you will be re-directed to a page within our main Merck Website.
In girls and women ages 9 to 45, GARDASIL® helps prevent infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: cervical, vaginal, and vulvar cancers caused by HPV types 16 and 18; abnormal and precancerous vaginal and vulvar lesions, abnormal and precancerous cervical lesions as found in Pap tests, caused by types 6, 11, 16 and 18; and genital warts caused by types 6 and 11.
In girls and women ages 9 to 26, GARDASIL® also helps protect against anal cancer caused by HPV types 16 and 18, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.
In boys and men ages 9 to 26, GARDASIL® helps protect against infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: anal cancer caused by HPV types 16 and 18, genital warts caused by types 6 and 11, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.
GARDASIL® helps prevent these diseases, but it does not treat them. And just like all vaccines, GARDASIL® may not fully protect everyone who gets it. GARDASIL® does not protect against all types of HPV. Duration of protection continues to be studied. GARDASIL® does not protect against other sexually transmitted infections.
Even if vaccinated with GARDASIL®, it is still important for women to continue having regular Pap tests. Recipients of GARDASIL® should not discontinue anal cancer screening if it has been recommended by a healthcare provider. Vaccination with GARDASIL® is not recommended during pregnancy.
Like all vaccines, GARDASIL® may cause some side effects. GARDASIL® has been shown to be generally well tolerated in adults and children as young as age 9. The most commonly reported side effects included pain, swelling, itching, bruising and redness where the shot was given, fever, nausea, dizziness, headache, vomiting and pain in extremity.
Fainting has been reported. Fainting can occur after vaccination, most commonly among adolescents and young adults. Although fainting episodes are uncommon, vaccinees should be observed for 15 minutes after they receive GARDASIL®.
Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives, and rash have been reported.
These were not all the side effects reported. If you notice any unusual or severe symptoms after receiving GARDASIL®, contact your healthcare professional as soon as possible.
Information about GARDASIL® is provided in the
To retrieve this information you will be re-directed to a page within our main Merck Website, which contains the Consumer Information.
Click here to go to the Gardasil® Consumer Information.
To view PDF documents, you must have Adobe Acrobat Reader® .
To view PDF documents, you must have Adobe Acrobat Reader®
By clicking on this link, you will be leaving this site
This link will take you to a site outside of Merck Canada Inc.
Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Merck site.
Proceed installed on your computer.
This site is intended only for residents of Canada. This Website is for information purposes only.
® Registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Used under license.
© 2010-2012 Merck Canada Inc., a subsidiary of Merck & Co., Inc. All rights reserved.